

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 03-465-D (400/151)	Serial No. 10/826,966
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		Applicant: McSwiggen et al.	
		Filing Date: April 16, 2004	Group: 1635

## U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
/TCG/	*	US-2002/0086356	03/30/01	Tuschl et al.			07/04/02
	*	US-2002/0151693	02/08/01	Breaker et al.			10/17/02
	*	US-2003/0064945	07/25/01	Akhtar et al.			04/03/03
	*	US-2003/0143732	08/30/02	Fosnaugh et al.			07/31/03
	*	US-2003/0190635	07/25/02	McSwiggen et al.			10/09/03
	*	US-2003/0206887	09/16/02	Morrissey et al.			11/06/03
	*	US-2004/0019001	07/26/02	McSwiggen et al.			01/29/04
	*	US-2005/0020521	09/25/03	Rana, Tariq M.			01/27/05
	*	US-2005/0182005	05/13/04	Tuschl et al.			02/18/05
/TCG/	*	US-2005/0227256	11/26/04	Hutvagner et al.			10/13/05

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
/TCG/	*	5,587,471	12/24/96	Cook et al.			
/TCG/	*	5,998,148	12/07/99	Bennett et al.			

EXAMINER /Terra Cotta Gibbs/	DATE CONSIDERED 05/31/2007
---------------------------------	-------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> (Rev. 2-32)	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b> 03-465-D (400/151)	<b>Serial No.</b> 10/826,966
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		<b>Applicant:</b> McSwiggen et al.	
		<b>Filing Date:</b> April 16, 2004	<b>Group:</b> 1635

/TCG/	*	5,998,206	12/07/99	Cowser			
↓	*	6,214,805	04/10/01	Torrence et al.			
↓	*	6,346,398	02/12/02	Pavco et al.			
↓	*	6,573,099	06/03/03	Graham et al.			
↓	*	6,824,972	11/30/04	Kenwick et al.			
/TCG/	*	7,078,196	07/18/06	Tuschl et al.			

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclasses	Translation	
							Yes	No
/TCG/	1.	08208687	08/13/96	JP (Hotoda et al.)	ABSTRACT ONLY			
↓	2.	03/044188	05/30/03	WO (Tei et al.)	ABSTRACT ONLY			
↓	3.	04/048566	11/21/03	WO (Saigo et al.)	ABSTRACT ONLY			
/TCG/	4.	05/049821	11/18/04	WO (Naito et al.)	ABSTRACT ONLY			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

/TCG/	5.	Alexeev et al., "Localized in vivo genotypic and phenotypic correction of the albino mutation in skin by RNA-DNA oligonucleotide," <i>Nature Biotechnology</i> , 18:43-47 (2000)
/TCG/	6.	Bayard et al., "Increased stability and antiviral activity of 2'-O-phosphoglycerol derivatives of (2'-5')oligo(adenylate)," <i>Eur. J. Biochem.</i> , 142(29):291-298 (1984)

<b>EXAMINER</b> /Terra Cotta Gibbs/	<b>DATE CONSIDERED</b> 05/31/2007
--	--------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> (Rev. 2-32)	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b>	<b>Serial No.</b>
<b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>		03-465-D (400/151)	10/826,966
(Use several sheets if necessary)		<b>Applicant:</b>	
		McSwiggen et al.	
		<b>Filing Date:</b>	<b>Group:</b>
		April 16, 2004	1635

/TCG/	7.	Bellon et al., "4-Thio-oligo- $\beta$ -D-ribonucleotides: synthesis of $\beta$ -4'-thio-oligouridylates, nuclease resistance, base pairing properties, and interaction with HIV-1 reverse transcriptase," <i>Nucleic Acids Research</i> , 21(7):1587-1593 (1993)
	8.	Bernstein et al., "The rest is silence," <i>RNA</i> , 7:1509-1521 (2001)
	9.	Bitko et al., "Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses," <i>BMC Microbiology</i> , 1:34 (2001)
	10.	Braasch et al., "Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression," <i>Biochemistry</i> , 31:14, 4503-4510 (2002)
	11.	Braasch et al., "RNA Inteference in Mammalian Cells by Chemically-Modified RNA," <i>Biochemistry</i> , 42, 7967-7975 (2003)
	12.	Caplen, Natasha J., "RNAi as a gene therapy approach," <i>Expert Opin. Biol. Ther.</i> , 3(4):575-586 (2003)
	13.	Claverie, Jean-Michel, "Fewer Genes, More Noncoding RNA," <i>Science</i> , 309, 1529-1530 (2005)
	14.	Czech, Michael P., "MicroRNAs as Therapeutic Targets," <i>The New England Journal of Medicine</i> , 354, 1194-1195 (2006)
	15.	Elbashir et al., "Analysis of gene function in somatic mammalian cells using small interfering RNAs," <i>Methods</i> , 26:199-213 (2002)
	16.	Hamasaki et al., "Short interfering RNA-directed inhibition of hepatitis B virus replication," <i>FEBS Letters</i> , 543:51-54 (2003)
	17.	Holen et al., "Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor," <i>Nucleic Acids Research</i> , 30:8, 1757-1766 (2002)
	18.	Hornung et al., "Sequence-specific potent induction of IFN- $\alpha$ by short interfering RNA in plasmacytoid dendritic cells through TLR7," <i>Nature Medicine</i> , 11, 263-270 (2005)
/TCG/	19.	Jen et al., "Suppression of gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," <i>Stem Cells</i> , 18:307-319 (2000)

EXAMINER	/Terra Cotta Gibbs/	DATE CONSIDERED	05/31/2007
----------	---------------------	-----------------	------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> (Rev. 2-32)  <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>SECOND SUPPLEMENTAL INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	<b>Atty. Docket No.</b>  03-465-D (400/151)	<b>Serial No.</b>  10/826,966
	<b>Applicant:</b>  McSwiggen et al.	
	<b>Filing Date:</b>  April 16, 2004	<b>Group:</b>  1635


/TCG/	20.	Judge et al., "Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA," <i>Nature Biotechnology</i> , 23(4):457-462 (2005)
	21.	Mattick, John S., "The Functional Genomics of Noncoding RNA", <i>Science</i> , 309, 1527-1528 (2005)
	22.	McCaffrey et al., "RNA interference in adult mice," <i>Nature</i> , 148, 38-39 (2002)
	23.	Monia et al., "Evaluation of 2'-Modified Oligonucleotides Containing 2'-Deoxy Gaps as Antisense Inhibitors of Gene Expression," <i>J. Biol. Chem.</i> 268:14514-14522 (1993)
	24.	Olie et al., "Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide," <i>Biochimica et Biophysica Acta</i> , 1576, 101-109 (2002)
	25.	Schmidt et al., "Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure," <i>Nucleic Acids Research</i> 24:573-581 (1996)
	26.	Sethupathy et al., "TarBase: A comprehensive database of experimentally supported animal microRNA targets," <i>RNA</i> , 12:192-197 (2006)
	27.	Thomson et al., "Activity of hammerhead ribozymes containing non-nucleotidic linkers," <i>Nucleic Acids Research</i> 21:5600-5603 (1993) (MAY BE REFERRED TO AS THOMPSON)
↓	28.	Vickers et al., "Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents," <i>Journal of Biological Chemistry</i> , 278, 7108-7118 (2003)
/TCG/	29.	Zhang et al., "Single Processing Center Models for Human Dicer and Bacterial RNase III," <i>Cell</i> , 118:57-68 (2004)

<b>EXAMINER</b>  /Terra Cotta Gibbs/	<b>DATE CONSIDERED</b>  05/31/2007
--	--


**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> (Rev. 2-32)	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b> 03-465-D (400/151)	<b>Serial No.</b> 10/826,966
<b>THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use several sheets if necessary)		<b>Applicant:</b> McSwiggen et al. <b>Filing Date:</b> April 16, 2004 <b>Group:</b> 1635	

## U.S. PATENT APPLICATION DOCUMENTS

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
	*	US-2003/0059944	09/13/02	Lois-Caballe et al.			03/27/03

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	*	6,060,456	05/09/00	Arnold et al.			

EXAMINER 	DATE CONSIDERED <u>5/31/07</u>
--	--------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.